Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) ...

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

Palliative radiation was allowed during treatment. Of all patients with mNSCLC enrolled ... CB, clinical benefit; ICI, immune checkpoint inhibitor; NSCLC, non–small cell lung cancer. From PROPHETIC, ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...